Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
Joann L. Ater(Children's Oncology Group), Ian F. Pollack(Children's Hospital of Pittsburgh), Michael D. Prados(University of California, San Francisco), Richard Sposto(Children's Hospital of Los Angeles), Ken H. Lazarus(Children's Oncology Group), Jeffrey H. Wisoff(NYU Langone Health), Claire Mazewski(Children's Oncology Group), Gilbert Vézina(Children's Oncology Group), David R. Freyer(University of Southern California), Emiko J. Holmes(Moffitt Cancer Center), Roger J. Packer(Children's Hospital of Philadelphia), Tianni Zhou(Children's Oncology Group), Timothy N. Booth(Children's Oncology Group)
Cited by 433
Related Papers
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
|JNCI Journal of the National Cancer Institute|2009|530
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488